Chi Podcasts

Dr. Ian Hunt of Novartis speaks to CHI on December 1, 2015. Dr. Hunt will be presenting during the Applying Expression Platforms conference at 2016’s PepTalk, January 18-22 in San Diego, California. Topics include development of high-throughput protein technologies and different strategies to make more difficult proteins, the recent explosion in technologies to solve X-ray crystallography of GPCRs, applying such technologies into the drug discovery context, generation of very large protein complexes and more. Find more information at http://www.CHI-PepTalk.com/

Peter Collins and Dr. Pepper Denman, both with Premaitha Health, spoke with Phillips Kuhl of CHI on October 30. Both Peter and Pepper will be speaking at CHI’s Third Annual Advances in Prenatal Molecular Diagnostics conference, taking place in Boston on November 16-18. Topics covered in the podcast include perspectives on the differences between the U.S. and European markets for cell-free DNA prenatal testing, including the pros and cons of conducting such testing in-house compared to sending samples out for testing by a service provider. Premaitha’s position regarding whether or not to extend testing to sub-chromosomal genetic aberrations, specifically micro-deletions, is also addressed. For more information, visit http://www.HealthTech.com/Prenatal-Diagnostics/

CHI chats with Rebekah S. Zimmerman, Ph.D., FACMG, Director, Clinical Genetics, Foundation for Embryonic Competence. Dr. Zimmerman discuss the latest technologies she and her non-profit lab are working with and developing, including how the non-profit lab is different from a typical PGD lab. Dr. Zimmerman is one of our speakers for the Advances in NGS and Other Technologies session at the Reproductive Genetic Diagnostics conference. For details, visit http://www.Healthtech.com/Reproductive-Genetic-Diagnostics

Dr. Niall Barron of Dublin City University speaks to CHI on August 28, 2015. Dr. Barron will be presenting during the Engineering Expression Systems conference at the 2015 PEGS Europe Summit, 2-6 November in Lisbon, Portugal. Topics include CHO cell line engineering, accelerating recombinant protein production with existing and novel expression platforms, challenges, microRNA manipulation to boost recombinant protein productivity and manufacturing of biopharmaceuticals in Ireland. For more information, please visit http://www.PEGSummitEurope.com/

CHI chats with Tanmoy Mukherjee, M.D., Assistant Clinical Professor, Obstetrics, Gynecology and Reproductive Science, Mount Sinai Hospital. Dr. Mukherjee discusses the current challenges facing reproductive specialists in regards to genetic diagnosis of recurrent pregnancy loss, as well as how NGS is affecting this type of testing Dr. Mukherjee is one of our speakers for the Clinical Applications for Advanced Testing Technologies session at the Reproductive Genetic Diagnostics conference. For details, visit http://www.healthtech.com/reproductive-genetic-diagnostics

CHI interviews Dr. Claudio Hetz, Professor in the Institute of Biomedical Sciences, and Principal Investigator in the Laboratory of Cellular Stress and Biomedicine at the University of Chile about the rapidly evolving drug discovery space of targeting the unfolded protein response (UPR) - particularly for cancers and neurodegenerative diseases. Discussion questions include: • Why has targeting components of the UPR emerged as a viable therapeutic strategy? (What are some of the recent critical discoveries that have propelled this field forward?) • What are emerging and promising therapeutic targets within the UPR and why? • What are some of the current challenges surrounding targeting the UPR? • You are giving a lecture during the upcoming Targeting the Unfolded Protein Response meeting, September 23-24 in Boston. Can you tell us a little about your work and what you hope to convey to attendees during the conference? • What are people within this space just now starting to think about? In other words, w

Bonus Podcast for CHI's interview with Drs. Trevor Perrior, Research Director at Domainex, and Gregg Siegel, CEO of ZoBio Listen to the full podcast here: https://soundcloud.com/chi-podcasts/histone-methyltransferase-and-demethylase-inhibitor-discovery Find more information about the conference here: http://www.DiscoveryOnTarget.com/

CHI interviews Drs. Trevor Perrior, Research Director at Domainex, and Gregg Siegel, CEO of ZoBio about the current challenges in developing novel chemical matter targeting HMTs and HDMs, novel tools and technologies enabling discovery, and emerging targets within this space. Discussion questions include: 1. How have you seen this field evolve over the past few years? 2. What are some of the challenges in developing novel chemical matter targeting these enzymes? 3. What are some of the tools and technologies that are aiding epigenetic inhibitor discovery? 4. What are some other interesting and emerging HMT or HDM targets? 5. You are giving a lecture during the upcoming Targeting Histone Methyltransferases and Demethylases meeting, part of Discovery on Target 2015 this September 23-24 in Boston. What do you hope to share with attendees during your lecture? Find more information at http://www.DiscoveryOnTarget.com/

Giulia Siravegna of the University of Torino and the IRCCS-Candiolo Cancer Institute discusses the recent study on the potential of circulating tumor DNA (ctDNA) to evaluate response to chemotherapy in colorectal cancer patients; how ctDNA will be used in conjunction with other tests in the standard of care for colorectal cancer; exciting applications emerging for liquid biopsies; and results from the recent liquid biopsy study published in Nature. Find more at http://www.NextGenerationDx.com/Cell-Free-DNA Watch the interview at https://youtu.be/JHD9YR4NYX0

CHI chats with Raymond J. Langley, Ph.D., Associate Research Scientist, Lovelace Respiratory Research Institute. Dr. Langley discusses his current work on metabolomics risk analysis models for sepsis as well as the challenges associated with them and other developing technology. Dr. Langley is the chair for our Direct Detection for Sepsis session and our Novel Technologies and Approaches session at the Molecular Diagnostics for Infectious Disease conference at the 2015 Next-Generation Diagnostics Summit. For details, visit http://www.NextGenerationDx.com/Infectious-Disease-Diagnostics

CHI chats with Kate Simon, Ph.D., Senior Consultant at Biologics Consulting Group, Incorporated. Dr. Simon discusses reference methods for new biomarkers of infectious diseases, how to establish reference methods, and the biggest challenges scientists are facing in this field in 2015 and beyond. Dr. Simon is the chair for our Molecular Point-of-Case Testing For ID session of the Molecular Diagnostics for Infectious Disease track at the 2015 Next-Generation Diagnostics Summit. For details, visit http://www.NextGenerationDx.com/Infectious-Disease-Diagnostics

Michael Roehrl of the UHN Program in BioSpecimen Sciences and Anthony Joshua of Princess Margaret Cancer Centre speak to CHI on June 2, 2015. Drs. Roehrl and Joshua will be co-presenting a Case Study of their biobanker/biouser partnership at the Leaders in Biobanking Congress, July 14-16 in Toronto, Canada. Topics include the Rapid Autopsy Program of Princess Margaret Cancer Centre, the mutual influence of lab research and clinical practice work, biospecimen management and collection of robust data, patient contributions to cancer research and understanding cancer therapy resistance. For more information visit http://www.Healthtech.com/Biobanking

CHI chats with Reiner Babiel, Ph.D., who is the Executive Director of Consulting at RBDC. Dr. Babiel discusses NGS in infectious disease diagnostics, key advancements in the field, and the upcoming Next-Generation Diagnostics Summit. Dr. Babiel is the chair for our NGS Sequencing in ID session of the Molecular Diagnostics for Infectious Disease track at the 2015 Next Generation Dx Summit. For details, visit http://www.NextGenerationDx.com/Infectious-Disease-Diagnostics

CHI interviews Dr. Xavier Jacq, Head of Biology at MISSION Therapeutics regarding drugging deubiquitinase enzymes (DUBs), a rapidly emerging target class with the Ubiquitin Proteasome System (UPS). Discussion topics and questions include: 1. Tell us a little about MISSION and your current programs. 2. Why are these emerging as viable therapeutic targets? 3. What are drug discovery challenges in this space? What about inhibitor discovery, how challenging is this? 4. What might be challenges surrounding translating these compounds into the clinic? 5. What are some novel tools and technologies being developed to overcome some of these challenges? 6. You are giving a lecture at the 13th Annual Discovery on Target Conference, during the Targeting the Ubiquitin Proteasome System meeting. What do you hope to convey to attendees during your lecture this fall? 7. How have you seen this field evolve over the past few years, and where do you see it going in the future? For more information visit http://

Suzanne Vercauteren of BC Children’s Hospital and University of British Columbia speaks to CHI on May 20, 2015. Dr. Vercauteren will be a presenter at the Leaders in Biobanking Congress, July 14-16 in Toronto, Canada. Topics include biospecimen collection and storage of clinical data at the BCCH BioBank, practices for ensuring biobank sustainability, ethical and operational considerations of planning an institutional biobank for children and women, and the importance of public engagement. For more information, visit http://www.Healthtech.com/Biobanking

CHI chats with Ally Dering-Anderson, BA, Pharm.D., RP, FAAIM, who is a Clinical Assistant Professor of Pharmacy at the University of Nebraska College of Pharmacy. Ally discusses legal considerations, collaborative care agreements, training, and the changing role of pharmacies. Ally will present a regulatory update for point-of-care diagnostics in the community pharmacy market at the 2015 Next Generation Dx Summit. For details, visit http://www.NextGenerationDx.com/Pharmacy-Diagnostics

Amid Zand interviews Dr. Patrick Hurban of Expression Analysis, a Quintiles Company on 30 April, 2015. Dr. Hurban will be speaking at the Knowledge Foundation & Cambridge Healthtech Institute’s Ninth International Sample Prep Technologies, June 25-26, in Bethesda, MD. His talk will examine use of NGS assays to compare results obtained from matched formalin-fixed and frozen tissue specimens. For more information visit http://www.SamplePrepConference.com/

CHI interviews Dr. Gabriela Chiosis, Associate Member and Lab Head of Molecular Pharmacology and Chemistry at Memorial Sloan Kettering Cancer Center about the trends, tools and challenges in developing chaperome-based therapeutics. Discussion questions include: 1. How have you seen this field evolve over the past few years? 2. Can you share with us what we have learned from discovery and clinical efforts thus far? 3. What tools have recently been developed, including those from your lab, that are currently advancing drug discovery in this space? 4. What are the remaining challenges surrounding drug discovery and development in this space? What has hindered FDA approvals? 5. You are giving a lecture during the upcoming Chemical Biology for Target Validation meeting, June 10-11 in Boston – part of the World Pharma Congress 2015. What do you hope to convey to attendees during your lecture? 6. Where do you see the greatest opportunities for continued development? For more information visit http://www.H

Mark Coflin, Senior Director of Alliance Management at Baxter Bioscience discusses his views on the changes in the alliance management landscape, the evolution of the AM function to meet growing demand, challenges in this space, and Baxter Bioscience’s new start in building world-class alliance management capabilities. For more information visit http://www.Healthtech.com/AMS

The field of immunotherapy is very exciting and holds great promise. This podcast will review limitations of monotherapy, and describe Dr. Curran’s approach for inducing an immune response through combination therapy. He will explain how this approach different from existing approaches and how it uses new strategies to overcome common limitations. Advice will be shared for selecting immunotherapy combinations and review applications emerging in combination therapy that are not possible with monotherapy. For more information go to http://www.PEGSummit.com/